One Case of Exfoliative Dermatitis Induced by Lamotrigine Tablets

Abstract

CLC Number:

R994.11

WANG Xing. One Case of Exfoliative Dermatitis Induced by Lamotrigine Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 244-245.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2019/V16/I4/244

[1] Reid J G, Gitlin M J, Altshuler L L. Lamotrigine in psychiatric disorders[J]. J Clin Psychiatry, 2013, 74(7): 675-84.
[2] Clark C T, Klein A M, Perel J M, et al. Lamotrigine dosing for pregnant patients with bipolar disorder[J]. Am J Psychiatry, 2013, 170(11):1240-7.
[3] 国家药典委员会. 临床用药须知: 化学和生物制品卷[M]. 2015版. 北京: 中国医药科技出版社, 2017:41.
[4] 何心, 张永, 徐进, 等.77例拉莫三嗪不良反应的文献分析[J].中国药物警戒. 2016,13(5): 303-305.
[5] Adam J, Pichler W J, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation[J]. British Journal of Clinical Pharmacology, 2011, 71(5):701-707.
[6] Wang X Q , Xiong J , Xu W H , et al. Risk of a lamotrigine-related skin rash: Current meta-analysis and postmarketing cohort analysis[J]. Seizure, 2015, 25:52-61.
[7] 赵建彬, 陈菲菲. 基于文献分析的拉莫三嗪不良反应初步评估[J]. 中国医院药学杂志, 2013, 33(12): 1014-1015.
[8] 刘立民, 江丹, 庞露, 等. 拉莫三嗪药动学及其影响因素研究进展[J]. 医药导报, 2013, 32(12): 1616-1621.
[9] Shi Y W, Min F L, Zhou D, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions[J]. Neurology, 2017, 88(23):2183-2191.
[10] Ko T M, Chung W H, Wei C Y, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome[J]. Journal of Allergy and Clinical Immunology, 2011, 128(6):1266-1276.
[11] Hirsch L J, Arif H, Nahm E A, et al. Cross-sensitivity of skin rashes with antiepileptic drug use[J]. Neurology, 2008, 71(19):1527-1534.
[12] Biton, Victor. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy[J]. Expert Opinion on Drug Metabolism & Toxicology, 2006, 2(6):1009-1018.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.

One Case of Exfoliative Dermatitis Induced by Lamotrigine Tablets

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics